Analyst Price Targets — CLLS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 7:36 am | Lukas Shumway | Barclays | $9.00 | $3.63 | StreetInsider | Barclays Starts Cellectis (CLLS) at Overweight |
| October 20, 2025 10:45 am | Nick Abbott | Wells Fargo | $4.00 | $3.98 | TheFly | Cellectis price target raised to $4 from $3 at Wells Fargo |
| October 17, 2025 9:23 am | Gena Wang | Barclays | $8.00 | $4.52 | TheFly | Cellectis price target raised to $8 from $4 at Barclays |
Latest News for CLLS
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer.
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CLLS.
Senate Trading
No Senate trades found for CLLS.
U.S. House Trading
No House trades found for CLLS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.